Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 10/20 | 0.71 |
| ▸ | USP2 | O75604 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | OSBP | P22059 | 1/20 | 0.52 |
| ▸ | RORC | P51449 | 1/20 | 0.52 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.52 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | POLA1 | P09884 | 1/20 | 0.51 |
| ▸ | TOP2A | P11388 | 1/20 | 0.51 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.49 |
| ▸ | CDC25A | P30304 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918378 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL15935529 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL6302509 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL15935854 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL288394 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL3425844 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL9454951 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL2216946 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL10389496 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 | |
| SCHEMBL19837228 | 1.00 | NPC1L1 (0.71) | NPC1L1USP2LMNAMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646421-A1 | FLUORO-OXYSTEROLS POSITRON EMISSION TOMOGRAPHY (PET) RADIOTRACERS | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-11-12 | — | — | EP | claimed |
| WO-2024227949-A1 | SCREENING AND USES OF GLUTAMINE SYNTHETASE MODULATORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-11-07 | — | — | WO | claimed |
| EP-4459280-A1 | SCREENING AND USES OF GLUTATHIONE SYNTHETASE MODULATORS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-11-06 | — | — | EP | claimed |
| WO-2024146880-A1 | FLUORO-OXYSTEROLS POSITRON EMISSION TOMOGRAPHY (PET) RADIOTRACERS | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-07-11 | — | — | WO | claimed |
| US-20120136581-A1 | Method of Diagnosing Asphyxia | BIOCRATES LIFE SCIENCES AG (AT) | 2012-05-31 | — | — | US | claimed |
| EP-2427773-A1 | METHOD OF DIAGNOSING ASPHYXIA | Keller, Matthias (DE) | 2012-03-14 | — | — | EP | claimed |
| WO-2010128054-A1 | METHOD OF DIAGNOSING ASPHYXIA | BIOCRATES LIFE SCIENCES AG (AT) | 2010-11-11 | — | — | WO | claimed |
| EP-2249161-A1 | Method of diagnosing asphyxia | BIOCRATES Life Sciences AG (AT) | 2010-11-10 | — | — | EP | claimed |
| WO-2025242860-A2 | PHYTOSTEROL DERIVATIVES, AND COMPOSITIONS COMPRISING THE SAME, FOR USE AS MEDICAMENTS | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-11-27 | — | — | WO | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| CN-114127306-B | Lipid modified oligonucleotides and methods of use thereof | 加利福尼亚大学董事会 | 2025-04-15 | — | — | CN | disclosed |
| US-20250114377-A1 | TWO-PRONGED TREATMENT FOR NIEMANN PICK TYPE C DISEASE | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2025-04-10 | — | — | US | disclosed |
| EP-4525880-A1 | TWO-PRONGED TREATMENT FOR NIEMANN PICK TYPE C DISEASE | University of Notre Dame du Lac (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20250066860-A1 | METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2025-02-27 | — | — | US | disclosed |
| US-20120136581-A1 | Method of Diagnosing Asphyxia | BIOCRATES LIFE SCIENCES AG (AT) | 2012-05-31 | — | — | US | disclosed |
| EP-2427773-A1 | METHOD OF DIAGNOSING ASPHYXIA | Keller, Matthias (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-20110177156-A1 | Sterol-Modified Amphiphilic Lipids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-07-21 | — | — | US | disclosed |
| WO-2010128054-A1 | METHOD OF DIAGNOSING ASPHYXIA | BIOCRATES LIFE SCIENCES AG (AT) | 2010-11-11 | — | — | WO | disclosed |
| EP-2249161-A1 | Method of diagnosing asphyxia | BIOCRATES Life Sciences AG (AT) | 2010-11-10 | — | — | EP | disclosed |
| US-20020107233-A1 | Steriodal derivatives | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177156-A1 | Sterol-Modified Amphiphilic Lipids | SREBF1, SREBF2, SGMS1 | NPC1L1 20/4885USP2 2160/4885LMNA 500/4885 |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | NPC1L1 14/4885USP2 2046/4885LMNA 161/4885 |
| US-20020107233-A1 | Steriodal derivatives | NR1H3, NR1H2, NR1H4 | NPC1L1 97/4885USP2 2470/4885LMNA 2923/4885 |
| US-20250114377-A1 | TWO-PRONGED TREATMENT FOR NIEMANN PICK TYPE C DISEASE | NPC1L1, NPC1, STING1 | NPC1L1 1/4885USP2 2106/4885LMNA 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.